Facultative heterochromatin

Facultative heterochromatin is a dynamic and reversible state of chromatin condensation that regulates gene expression by restricting access to the transcriptional machinery (Nature Reviews Genetics, 2007). Unlike constitutive heterochromatin, which is permanently silenced, facultative heterochromatin is cell-type specific and responds to developmental or environmental cues (Cell, 2012). In immune and epithelial cells, this state is crucial for maintaining lineage identity and controlling the timing of gene activation during differentiation or stress responses (Nature Immunology, 2013). It is primarily characterized by the presence of the H3K27me3 epigenetic mark, which is established by the Polycomb Repressive Complex 2 (PRC2) (Science, 2002). Dysregulation of facultative heterochromatin is a hallmark of many diseases, including various cancers where it can lead to the silencing of tumor suppressor genes (Nature Reviews Cancer, 2016). In the context of inflammation, changes in heterochromatin stability can result in the aberrant expression of pro-inflammatory cytokines (Journal of Experimental Medicine, 2011). While facultative heterochromatin itself is a structural state rather than a single protein, it is a major focus of therapeutic intervention through the targeting of its regulatory enzymes (Clinical Epigenetics, 2020). Drugs such as EZH2 inhibitors (e.g., tazemetostat) and histone deacetylase inhibitors are used to modulate these regions and restore normal cellular function (FDA, 2020). Therapeutic challenges include the potential for widespread off-target effects due to the global nature of chromatin remodeling (Trends in Pharmacological Sciences, 2015). Monitoring biomarkers like H3K27me3 levels is essential for evaluating the efficacy of treatments targeting these epigenetic structures (Molecular Cancer, 2021).

Other names

Condensed chromatinSilenced chromatinH3K27me3-enriched chromatinPolycomb-repressed chromatin

Modulation of epigenetic modifying enzymes such as histone methyltransferases (e.g., EZH2) and histone deacetylases (HDACs) to alter chromatin accessibility and gene expression.